ZVA Stock Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cellectis S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.34 |
52 Week High | €3.19 |
52 Week Low | €0.88 |
Beta | 3.13 |
1 Month Change | -7.15% |
3 Month Change | -22.50% |
1 Year Change | 21.67% |
3 Year Change | -85.40% |
5 Year Change | -85.98% |
Change since IPO | -82.70% |
Recent News & Updates
Recent updates
Shareholder Returns
ZVA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 6.5% | 2.1% | 1.9% |
1Y | 21.7% | 37.0% | 7.3% |
Return vs Industry: ZVA underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: ZVA exceeded the German Market which returned 7.3% over the past year.
Price Volatility
ZVA volatility | |
---|---|
ZVA Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ZVA's share price has been volatile over the past 3 months.
Volatility Over Time: ZVA's weekly volatility has decreased from 27% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 234 | Andre Choulika | https://www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.
Cellectis S.A. Fundamentals Summary
ZVA fundamental statistics | |
---|---|
Market cap | €177.80m |
Earnings (TTM) | -€66.40m |
Revenue (TTM) | €22.65m |
7.8x
P/S Ratio-2.7x
P/E RatioIs ZVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZVA income statement (TTM) | |
---|---|
Revenue | US$24.53m |
Cost of Revenue | US$1.26m |
Gross Profit | US$23.26m |
Other Expenses | US$95.15m |
Earnings | -US$71.89m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.00 |
Gross Margin | 94.86% |
Net Profit Margin | -293.13% |
Debt/Equity Ratio | 41.4% |
How did ZVA perform over the long term?
See historical performance and comparison